[Market Focus] Rokit Healthcare Surges on Hopes for US Entry of World's First AI Organ Regeneration Platform

Rokit Healthcare shares are showing strong performance. Investor sentiment appears to be rising due to growing expectations for the entry of its organ regeneration platform technology, which combines artificial intelligence (AI) and biotechnology, into the US market.

As of 9:46 a.m. on May 14, Rokit Healthcare shares were trading at 17,000 won, up 9.32% from the previous day.

Rokit Healthcare is a specialized company focusing on an AI-based, ultra-personalized organ regeneration platform. The company has developed and platformized a bio-ink production kit for making patches, wound modeling software utilizing AI, and the world's first medical 3D bioprinter. This platform has completed approval from the US Food and Drug Administration (FDA) and CE MDR certification for medical devices in Europe, and is currently being sold in 46 countries.

Recently, Rokit Healthcare's US partner, Tides Medical, signed an official supply agreement with Vizient, the largest healthcare group purchasing organization (GPO) network in the United States. The supply contract for the wound regeneration system 'APLICOR 3D,' which incorporates Rokit Healthcare's AI-powered ultra-personalized tissue regeneration platform technology, is seen as a significant step towards commercialization.

This content was produced with the assistance of AI translation services.